Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Mangoceuticals (MGRX) Gross Margin (2023 - 2025)

Mangoceuticals (MGRX) has disclosed Gross Margin for 3 consecutive years, with 50.31% as the latest value for Q4 2025.

  • Quarterly Gross Margin fell 2580.0% to 50.31% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 54.91% through Dec 2025, down 679.0% year-over-year, with the annual reading at 54.91% for FY2025, 679.0% down from the prior year.
  • Gross Margin hit 50.31% in Q4 2025 for Mangoceuticals, down from 60.42% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 76.11% in Q4 2024 to a low of 42.77% in Q2 2024.
  • Historically, Gross Margin has averaged 58.88% across 3 years, with a median of 58.66% in 2023.
  • Biggest five-year swings in Gross Margin: skyrocketed 1776bps in 2024 and later crashed -2580bps in 2025.
  • Year by year, Gross Margin stood at 58.35% in 2023, then skyrocketed by 30bps to 76.11% in 2024, then crashed by -34bps to 50.31% in 2025.
  • Business Quant data shows Gross Margin for MGRX at 50.31% in Q4 2025, 60.42% in Q3 2025, and 53.51% in Q2 2025.